Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
B
Beatriz Cuevas
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Faculty Researcher
17 h-index
94 pubs
908 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Beatriz Cuevas's research focuses on the clinical outcomes and treatment of myeloproliferative neoplasms (MPNs) and related hematological disorders. Her work has investigated the impact of COVID-19 on patients with MPNs, including mortality rates and specific risks associated with conditions like essential thrombocythemia. Cuevas has also examined the safety and efficacy of targeted therapies, such as asciminib and ruxolitinib, in real-world clinical practice for patients with chronic myeloid leukemia (CML) and polycythemia vera. Her research extends to the application of machine learning in improving risk stratification for myelofibrosis, utilizing data from patient registries. Cuevas holds an h-index of 17 with 94 total publications and 908 total citations.
Metrics
- h-index: 17
- Publications: 94
- Citations: 908
Selected Publications
-
Contrastive Learning for Conversational Emotion Recognition Using Knowledge Enhancement of Large Language Models (2025)
Collaboration Network
Top Collaborators
Alberto Álvarez‐Larrán
26 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Showing 5 of 26 shared publications
María Laura Fox
Vall d'Hebron Hospital Universitari (ES)
26 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
Showing 5 of 26 shared publications
Francisca Ferrer‐Marín
Hospital General Universitario Morales Meseguer (ES)
21 shared publications
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
Showing 5 of 21 shared publications
Manuel Pérez‐Encinas
Complejo Hospitalario Universitario de Santiago (ES)
20 shared publications
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Showing 5 of 20 shared publications
Anna Angona
18 shared publications
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
Showing 5 of 18 shared publications
María Teresa Gómez‐Casares
Hospital Universitario de Gran Canaria Doctor Negrín (ES)
18 shared publications
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
- Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Showing 5 of 18 shared publications
Mercedes Gasior Kabat
Hospital Universitario La Paz (ES)
15 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Long-term follow-up of recovered MPN patients with COVID-19
- Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Showing 5 of 15 shared publications
Valentín García‐Gutiérrez
Hospital Universitario Ramón y Cajal (ES)
15 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
Showing 5 of 15 shared publications
Eduardo Arellano‐Rodrigo
Hospital Clínic de Barcelona (ES)
12 shared publications
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
Showing 5 of 12 shared publications
María Ángeles Foncillas
Hospital Universitario Infanta Leonor (ES)
11 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Long-term follow-up of recovered MPN patients with COVID-19
- Second versus first wave of COVID-19 in patients with MPN
- Determinants of early triage for hospitalization in myeloproliferative neoplasm (<scp>MPN)</scp> patients with <scp>COVID</scp>‐19
Showing 5 of 11 shared publications
Elvira Mora
Hospital Universitario La Paz (ES)
11 shared publications
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
Showing 5 of 11 shared publications
Gonzalo Carreño‐Tarragona
Hospital Universitario 12 De Octubre (ES)
11 shared publications
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Long-term follow-up of recovered MPN patients with COVID-19
- Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
- DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study
- Detection of Kinase Domain Mutations in BCR-ABL1 Leukemia by Ultra-deep Sequencing of Genomic DNA
Showing 5 of 11 shared publications
Patricia Vélez
Hospital Del Mar (ES)
11 shared publications
- Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
- Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
- Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
- The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis
Showing 5 of 11 shared publications
Elena Maria Elli
Azienda Ospedaliera San Gerardo (IT)
10 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Long-term follow-up of recovered MPN patients with COVID-19
- Second versus first wave of COVID-19 in patients with MPN
Showing 5 of 10 shared publications
Francesca Palandri
Istituto di Ematologia di Bologna (IT)
10 shared publications
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
- Long-term follow-up of recovered MPN patients with COVID-19
- Second versus first wave of COVID-19 in patients with MPN
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics
Aaron J. Scott
University of Arkansas for Medical Sciences
COVID-19 Clinical Research Studies
Cancer Treatment and Pharmacology
Health disparities and outcomes
Tom Menzies
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
Robert Spraggins
University of Arkansas for Medical Sciences
COVID-19 Clinical Research Studies
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
A. Chalamalla
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
Machine Learning Applications
Jacob T. Painter
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
Milena Neves De Miranda
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes